TY - JOUR
T1 - The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases
T2 - An Updated Systematic Review
AU - Albano, Domenico
AU - Rizzo, Alessio
AU - Slart, Riemer H.J.A.
AU - Hess, Søren
AU - Noriega-Álvarez, Edel
AU - Wakfie-Corieh, Cristina Gamila
AU - Leccisotti, Lucia
AU - Glaudemans, Andor W.J.M.
AU - Gheysens, Olivier
AU - Treglia, Giorgio
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/5/31
Y1 - 2024/5/31
N2 - The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease, investigated in six studies for a total of 200 patients, followed by bone and joint diseases in two studies and 185 patients, IgG4-related disease in 53 patients, and Crohn's disease in 30 patients. Despite the heterogeneity of studies in terms of study design and technical features, FAPI PET/CT showed a high detection rate and diagnostic role. Moreover, when compared with 2-[
18F]FDG PET/CT (
n = 7 studies), FAPI PET/CT seems to have better diagnostic performances. The presence of chronic inflammation and tissue remodeling, typical of immune-mediated inflammatory conditions, may be the underlying mechanism of FAPI uptake.
AB - The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease, investigated in six studies for a total of 200 patients, followed by bone and joint diseases in two studies and 185 patients, IgG4-related disease in 53 patients, and Crohn's disease in 30 patients. Despite the heterogeneity of studies in terms of study design and technical features, FAPI PET/CT showed a high detection rate and diagnostic role. Moreover, when compared with 2-[
18F]FDG PET/CT (
n = 7 studies), FAPI PET/CT seems to have better diagnostic performances. The presence of chronic inflammation and tissue remodeling, typical of immune-mediated inflammatory conditions, may be the underlying mechanism of FAPI uptake.
KW - FAPI
KW - hybrid imaging
KW - infection
KW - inflammation
KW - nuclear medicine
KW - PET
UR - https://www.scopus.com/pages/publications/85197121695
U2 - 10.3390/ph17060716
DO - 10.3390/ph17060716
M3 - Review article
C2 - 38931383
SN - 1424-8247
VL - 17
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 6
M1 - 716
ER -